Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis

Cancer Treatment Reviews (2014) - Comments
pubmed: 24112812 doi: 10.1016/j.ctrv.2013.09.004 issn: 1532-1967 issn: 0305-7372

James Signorovitch, Rajeev Ayyagari, William M. Reichmann, Eric Q. Wu, Lei Chen